相关临床试验
102
28 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1823
进行中（未招募）
20
19.6%
已完成
38
37.3%
尚未招募
8
7.8%
招募中
14
13.7%
暂停
3
2.9%
终止
7
6.9%
Unknown
9
8.8%
撤回
3
2.9%
暂无批准数据
- Paddington Life Sciences, hosted by Imperial College Healthcare NHS Trust, has been selected to lead a new London-wide Life Sciences Talent Hub connecting employers, educators, healthcare organisations and innovation partners. - The hub forms part of the Mayor of London's £3.2 million investment programme to create fair, inclusive and sustainable employment and training opportunities across the capital. - Partners include the Knowledge Quarter, SC1 London, White City, Barts Life Sciences, and the Inclusive Health and Life Sciences Coalition, with £1 million in funding allocated to the hub. - The initiative aims to strengthen talent pipelines and build a diverse, skilled workforce to sustain London's position as a global life sciences leader.
- A first-in-human study confirms high-intensity focused ultrasound (HIFU) can safely block abnormal placental blood vessels in early-onset twin-to-twin transfusion syndrome (TTTS). - The non-invasive procedure successfully blocked blood flow in 90% of treated vessels with no adverse side effects, though half of the 10 participants required further treatment. - Researchers are now planning a larger trial of 50 to 100 women to determine whether HIFU can stabilize or reverse TTTS as an alternative to invasive laser therapy. - TTTS affects 10–15% of identical twins sharing a placenta, representing approximately 300–400 pregnancies annually in the UK, with potentially fatal outcomes if untreated.
- The Fleming Initiative and Cepheid have launched TRACE-CPE, a 30-month real-world study at two major London NHS Trusts to evaluate rapid molecular screening for carbapenemase-producing Enterobacterales (CPE). - The study compares rapid molecular diagnostics delivering results in approximately one hour against current culture-based screening that typically takes around 48 hours. - CPE is classified by the WHO as a critical-priority pathogen, and UKHSA data show acquired carbapenemase-producing organisms in England more than doubled between 2021 and 2023. - Findings aim to provide policymakers and clinicians with evidence on how rapid CPE screening should be deployed across the NHS and comparable health systems facing drug-resistant infections.
- GSK and the Fleming Initiative announced six new research programs using advanced AI to tackle antimicrobial resistance, with £45 million in funding over three years starting in early 2026. - The programs target critical challenges including Gram-negative bacterial infections, fungal diseases, and Staphylococcus aureus vaccine development using supercomputing and machine learning models. - According to the WHO GLASS Report, one in six bacterial infections are now antibiotic-resistant, with AMR deaths projected to rise 74.5% from 4.71 million in 2021 to 8.22 million by 2050. - The collaboration will create approximately 50 new scientific roles and make AI models freely available to researchers worldwide to accelerate antimicrobial drug development.
- The SepTiC study aims to refine sepsis treatment by addressing key questions regarding rapid testing, fluid management, and immune system support. - Rapid PCR testing is being used to identify infections quickly, potentially reducing the use of broad-spectrum antibiotics and combating antimicrobial resistance. - The trial is evaluating whether reducing excess fluid in patients whose condition is improving can aid organ recovery and improve outcomes. - Researchers are also assessing if the immune-stimulating medication GM-CSF (Sargramostim) can lower the risk of subsequent infections and enhance recovery in sepsis patients.
